42 results on '"Verstockt S"'
Search Results
2. DOP43 Histologic improvement, attenuation of inflammation and microbiome modulation by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitis
3. P573 Simplified MARIA score does not predict long-term outcomes in Crohn’s disease patients undergoing modified side-to-side strictureplasty for extensive ileitis
4. OP32 TWIST1-mediated fibroblast activation protein (FAP)-expressing fibroblasts drives fibrosis in Crohn’s Disease
5. P1191 Genetic determinants for smoking behaviour improve our understanding of sporadic versus familial Inflammatory Bowel Disease
6. P049 The lipidome of creeping fat in Crohn’s disease points towards a harmful microenvironment
7. P351 The Histo-endoscopic Spectrum in Ulcerative Colitis reveals a Distinct Mucosal Transcriptome for Histo-endoscopic Remission
8. P921 FMT in UC is associated with a decrease in Bacteroides-2 enterotype and response with baseline RNA and microbiota signatures
9. P005 0190Molecular-based classification of ulcerative colitis and its dynamic
10. DOP33 Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s disease
11. P112 S1PR expression on circulating immune cells is not limited to lymphocytes in patients with inflammatory bowel disease
12. OP01 Sequencing-based gene network analysis reveals a profound role for ferroptosis key gene GPX4 in post-operative endoscopic recurrence in Crohn’s disease
13. DOP08 Transcriptional signatures of blood derived immune cells associated with disease location-based heterogeneity in IBD
14. P030 Distinct molecular profiles between idiopathic cryptoglandular and Crohn-related perianal fistulas
15. P004 Microbiota, not host origin drives ex vivo epithelial response in ulcerative colitis patients and non-IBD controls
16. P027 Epithelial cells of patients with ulcerative colitis do not show an increased sensitivity after microbiota stimulation compared to non-IBD controls
17. DOP22 Integrative -omic analysis reveals microbiota mediated molecular mechanisms influencing host mucosal gene expression in Crohn’s Disease
18. P095 Initial disease course in a Belgian, prospective inception cohort of patients with inflammatory bowel disease: the PANTHER cohort
19. P062 Effects of exposure to steroids on the PredictSURE whole blood prognostic assay in Inflammatory Bowel Disease
20. OP14 Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD
21. Extracellular Vesicles in Inflammatory Bowel Disease: Small Particles, Big Players
22. DOP31 Serum protein markers for early and differential IBD diagnosis validated by machine learning approaches
23. P061 The molecular landscape of perianal fistula in Crohn’s disease: opportunities for new therapeutic approaches
24. OP30 The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn’s disease
25. P385 A mucosal marker predicting tofacitinib induced an endoscopic response in ulcerative colitis
26. P820 An easy and rapid targeted next generation sequencing-based genotyping assay for the validated IBD risk loci
27. OP15 Multi-omic data integration with network analysis reveals underlying molecular mechanisms driving Crohn’s disease heterogeneity
28. DOP38 A vedolizumab specific four-gene colonic signature accurately predicting future endoscopic remission in patients with inflammatory bowel disease
29. P827 Up-regulation of IL17-related pathways in affected colon from ulcerative colitis compared with Crohn’s disease
30. DOP70 An integrated multi-omics biomarker predicting endoscopic response in ustekinumab treated patients with Crohn's disease
31. P820 Molecular changes in non-inflamed terminal ileum in patients with ulcerative colitis
32. P821 Distinct and common gene expression profiles between inflamed ileum and colon of newly diagnosed CD patients
33. P385 TREM1, the first anti-TNF specific biomarker guiding therapeutic decision
34. P042 Decreased leukocyte trafficking may contribute to vedolizumab refractory disease after anti-TNF exposure in patients with ulcerative colitis
35. P035 Serum markers predict outcome to ustekinumab in patients with refractory Crohn’s disease and provide insides in the mechanism of action
36. OP003 Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
37. P010 Serum proteomic profiling in Crohn’s disease patients undergoing ileocolonic resection reveals discriminative inflammatory markers for endoscopic recurrence
38. P104 Gene expression profiles in inflamed colonic biopsies from newly diagnosed Crohn’s disease and ulcerative colitis patients differ depending on the age at diagnosis
39. P117 Serum proteomic analysis characterises newly diagnosed Crohn’s disease and ulcerative colitis depending on the age at diagnosis
40. P084 Ileal gene expression changes are associated with colonic disease activity in patients with ulcerative colitis
41. P035 TNF-driven pathways are increased at baseline in Crohn's disease patients not responding to infliximab
42. P067 Molecular profiling of early Crohn's disease reveals a prominent role for WNT5A
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.